TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10416734
Drug: 23.7 mg
Normalized name: vardenafil 20 MG (vardenafil HCl 23.7 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23.7 mg saccharin alone
Study: 7437263
Drug: Intravenous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prednisolone (doses of 16, 32, 48, and 64 mg)
Study: 7437263
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (100 mg)
Study: 7437263
Drug: Intravenous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prednisolone (all doses)
Study: 31076261
Drug: Alirocumab 75/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75/150 mg or 150 mg every 2 weeks
Study: 29899426
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once/day (group A)
Study: 29899426
Drug: Levofloxacin 200
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 200 mg twice/day (group B)
Study: 20055751
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate (ACE 12 mg; 3 mg every 3 months and 2 mg every 2 months)
Study: 20055751
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral ibandronate (ACE 5.5 mg; 2.5 mg daily)
Study: 20055751
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate (ACE 12 mg)
Study: 17394255
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular injection of 0.6 mg/kg dexamethasone
Study: 16360965
Drug: Carvedilol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (50 mg/day for ≤75 kg or 100 mg/day for >75 kg)
Study: 7317308
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy with Imipramine
Study: 7317308
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy with placebo
Study: 7317308
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy with Imipramine
Study: 29781483
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil 0.31 g d‐1
Study: 29781483
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil 0.62 g d‐1
Study: 29781483
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil 1.24 g d‐1
Study: 26707220
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine (PCV/PPV)
Study: 26707220
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine (PPV) only
Study: 11668312
Drug: Doxycycline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (150 mg daily)
Study: 7780294
Drug: 40‐mg intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40‐mg intravenous cocaine injections
Study: 3182119
Drug: Tulobuterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol (2 mg, twice daily)
Study: 3182119
Drug: Fenoterol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (2.5 mg, thrice daily)
Study: 24820831
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no probiotic medication)
Study: 22285946
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg CLMWF
Study: 18669464
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg orally once daily for 4 weeks, followed by 2 weeks off)
Study: 18669464
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (9 million units subcutaneous injections, three times weekly)
Study: 12736474
Drug: Torasemide at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide at 4-8 mg/day
Study: 12736474
Drug: Furosemide at
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide at 20-40 mg/day
Study: 10230947
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (CaCl2) 10 mg/kg administered simultaneously with propofol
Study: 10230947
Drug: Saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered simultaneously with propofol
Study: 8653836
Drug: Hydralazine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine at 10 μg/min (control)
Study: 7904993
Drug: Roxatidine 75
Normalized name: roxatidine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine 75 mg twice daily
Study: 7904993
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg 3 times a day and 400 mg at bed time
Study: 3327445
Drug: Intravenous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous indomethacin 0.35 mg/kg followed by an infusion of 0.07 mg/kg/h for 24 h
Study: 31948661
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid (O-3FA) 4 g/day
Study: 23057804
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen (10 mg/kg on day 1, 5 mg/kg on day 2, and 5 mg/kg on day 3)
Study: 6628498
Drug: Propranolol (2-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2-16 mg)
Study: 6628498
Drug: Pindolol (0.2-1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (0.2-1.6 mg)
Study: 31292608
Drug: levcromakalim (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: levcromakalim (0.05 mg/min)
Study: 28203319
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (37 mg of elemental iron daily for 3 weeks)
Study: 25791612
Drug: Mirabegron administered
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron administered as a single oral dose under fasted conditions.
Study: 25791612
Drug: Mirabegron administered
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron administered once daily under fed conditions for 8 days after a washout period.
Study: 25791612
Drug: Mirabegron administered
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron administered with low-fat and high-fat meals.
Study: 14679118
Drug: Cisplatin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (25 mg/m²) and Docetaxel (20 mg/m²) administered on days 1, 8, and 15 every 4 weeks
Study: 11354452
Drug: Additional scrubbing
Normalized name: Scrub-Stat
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Additional scrubbing of toe clefts with a gauze swab soaked in topical antiseptic.
Study: 11354452
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation with antiseptic between the toes.
Study: 7905101
Drug: Intraarterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial infusion of 17 beta‐oestradiol
Study: 7905101
Drug: Patch administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patch administration of 17 beta‐oestradiol
Study: 7905101
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of oestradiol
Study: 3139909
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg Euphyllin (theophylline)
Study: 3139909
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg Euphyllin (theophylline)
Study: 22906685
Drug: Physostigmine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (1 mg/h)
Study: 12560299
Drug: alfentanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 20 microg x kg(‐1), lidocaine 1.5 mg x kg(‐1), propofol 3 mg x kg(‐1) (Group I; n = 40)
Study: 12560299
Drug: fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 2 microg x kg(‐1), lidocaine 1.5 mg x kg(‐1), propofol 3 mg x kg(‐1) (Group II; n = 40)
Study: 10716371
Drug: 350 microg
Normalized name: Norethindrone 350 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 microg of the lipopeptide immunogen administered on days 0, 28, and 56 to HLA-selected subjects (4 subjects)
Study: 10716371
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered according to a similar inoculation schedule to HLA-selected subjects (3 subjects)
Study: 10716371
Drug: 350 microg
Normalized name: Norethindrone 350 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 microg of the lipopeptide immunogen administered to HLA-mismatched subjects (2 subjects)
Study: 3544940
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg body weight diazepam (Group A)
Study: 3544940
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg body weight midazolam (Group B)
Study: 17391383
Drug: Amoxycillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin-clavulanic acid 625 mg, four times daily for 3 days
Study: 17391383
Drug: Amoxycillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin-clavulanic acid 625 mg, four times daily for 10 days
Study: 16141426
Drug: Dipyridamole/Aspirin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole/Aspirin (200 mg dipyridamole/25 mg aspirin twice a day)
Study: 16141426
Drug: Dipyridamole/Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole/Aspirin
Study: 215011
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of double stranded RNA from f2-phage
Study: 25693055
Drug: Corticosteroids for
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids for ∼9 months and a maximum of six 500‐mg fixed‐dose intravenous (IV) cyclophosphamide (CYC) pulses, every 2‐3 weeks, then maintenance azathioprine or methotrexate.
Study: 25693055
Drug: Corticosteroids for
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids for ∼26 months combined with 500 mg/m2 IV CYC pulses, every 2‐3 weeks until remission, then maintenance for GPA or MPA patients and for those with EGPA or PAN with a Five‐Factors Score (FFS) of ≥1.
Study: 11179125
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose of salbutamol (400 microg)
Study: 11179125
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose of salbutamol (800 microg)
Study: 11179125
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of salbutamol (50, 100, or 400 microg)
Study: 11179125
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose of salbutamol (50+50+100+200 or 100+100+200+400 or 400+0+0+0 or 0+0+0+0 microg)
Study: 9788413
Drug: Irradiation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation with doses under 50 Gy in T1-2 tumors
Study: 9788413
Drug: Irradiation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation with doses below 50 Gy in T3-4 tumors
Study: 9788413
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of irradiation and wide local tumor excision
Study: 8141197
Drug: 0.75% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% metronidazole gel 5 gm twice daily for 5 days
Study: 18656571
Drug: Stage of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage of change (action vs contemplation/preparation)
Study: 18656571
Drug: Daily servings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily servings of fruit and vegetable intake
Study: 18656571
Drug: Understanding of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Understanding of vitamin pills
Study: 8706450
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (polymerized bovine hemoglobin)
Study: 8706450
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion of lactated Ringer's solution
Study: 6360817
Drug: Prostaglandin synthesis
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin synthesis inhibitors (acetylsalicyclic acid or indomethacin) during cytostatic infusion
Study: 29985202
Drug: High-intensity statin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin, maximally tolerated angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker, and low-dose aspirin
Study: 29985202
Drug: Conservative empiric
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative empiric treatment or further diagnostic evaluation of the coronary microvasculature
Study: 29985202
Drug: Traditional antianginal
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional antianginal and antiatherosclerotic medications
Study: 19470941
Drug: nab-paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel 100 mg/m(2) weekly
Study: 19470941
Drug: nab-paclitaxel 150
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 150 mg/m(2) weekly
Study: 19495958
Drug: nab-paclitaxel 300
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 300 mg/m(2) q3w
Study: 16533865
Drug: Paroxetine (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (21 days treatment)
Study: 8938165
Drug: Ultrasound-guided percutaneous
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided percutaneous acetic acid injection (15%, 20%, 30%, 40%, and 50% concentration)
Study: 8938165
Drug: Percutaneous acetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous acetic acid injection alone
Study: 8938165
Drug: Percutaneous acetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous acetic acid injection after transcatheter arterial embolization
Study: 1410729
Drug: ASL 900
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASL 900 mg and meperidine 100 mg/8 h (Group C)
Study: 1410729
Drug: ASL 900
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASL 900 mg and 1.800 mg/8 h together with meperidine 100 mg/8 h (Group D)
Study: 1410729
Drug: meperidine 50
Normalized name: meperidine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 50 mg and 100 mg/8 h (Group G)
Study: 1410729
Drug: meperidine 50
Normalized name: meperidine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 50 mg and 100 mg/8 h together with ASL 1.800 mg/8 h (Group H)
Study: 1410729
Drug: ASL 900
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASL 900 mg and 1.800 mg/8 h (Group A)
Study: 1410729
Drug: ASL 900
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASL 900 mg and 3.600 mg/8 h (Group B)
Study: 1410729
Drug: meperidine 50
Normalized name: meperidine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 50 mg and ASL 1.800 mg/8 h (Group E)
Study: 1410729
Drug: meperidine 50
Normalized name: meperidine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 50 mg and ASL 3.600 mg/8 h (Group F)
Study: 28967706
Drug: Letermovir 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letermovir 80 mg twice daily for 7 days with CsA 50 mg
Study: 28967706
Drug: Letermovir 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letermovir 80 mg twice daily for 11 days with TAC 5 mg
Study: 28967706
Drug: Letermovir 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letermovir 40 mg twice daily for 14 days with CsA 50 mg
Study: 28967706
Drug: Letermovir 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letermovir 40 mg twice daily for 14 days with CsA 200 mg
Study: 26484738
Drug: Robotic radiosurgery
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic radiosurgery (single-session, frameless, image-guided); tumor dose of 18-22 Gy (mean 20.3 Gy) prescribed to the 70% isodose line.
Study: 22248392
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg daily plus standard care
Study: 22248392
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (surgical debridement + culture-specific antibiotics + offloading + glycaemic control)
Study: 10513830
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg + Indapamide 0.625 mg (Per/Ind)
Study: 10513830
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg + Indapamide 0.625 mg (Per/Ind) in ISH subgroup
Study: 6181329
Drug: Endralazine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endralazine (10-20 mg t.i.d.)
Study: 6181329
Drug: Dihydralazine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (25-50 mg t.i.d.)
Study: 30657853
Drug: Pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 or 10 mg/kg Q3W
Study: 26453968
Drug: Daclatasvir 30mg
Normalized name: DACLATASVIR 30MG TAB
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir 30mg plus simeprevir 150mg once daily without ribavirin
Study: 26453968
Drug: Daclatasvir 30mg
Normalized name: DACLATASVIR 30MG TAB
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir 30mg plus simeprevir 150mg once daily with ribavirin
Study: 22018509
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g DHA-rich fish oil
Study: 22018509
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g EPA-rich fish oil
Study: 22018509
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g olive oil)
Study: 7862879
Drug: Theobromine (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobromine (560 mg)
Study: 2492454
Drug: t‐PA (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA (1.5 mg/kg/4 hr) and heparin (10,000 units bolus)
Study: 2492454
Drug: t‐PA (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA (1.5 mg/kg/4 hr) only
Study: 2492454
Drug: t‐PA and
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA and heparin
Study: 1095107
Drug: Penicillin drugs
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin drugs (control group)
Study: 31670790
Drug: Low-dose acupuncture
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acupuncture (DP)
Study: 31670790
Drug: High-dose acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acupuncture (DPTN)
Study: 30623408
Drug: PAC‐14028 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC‐14028 cream 0·1%
Study: 30623408
Drug: PAC‐14028 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC‐14028 cream 0·3%
Study: 30623408
Drug: PAC‐14028 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC‐14028 cream 1·0%
Study: 26415793
Drug: 6, 8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6, 8, 10, 12, or 14 mg intrathecal hyperbaric ropivacaine with 5 μg sufentanil
Study: 22535635
Drug: Standard dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysis therapy with constant ultrafiltration (UF) rate, cool dialysate and high sodium conductivity (Treatment A)
Study: 22535635
Drug: Dialysis regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis regimens with adjunctive interventions including blood volume (BV) control (Treatment B)
Study: 22535635
Drug: Dialysis regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis regimens with the combination of BV and active blood temperature control (Treatment C)
Study: 11106122
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (A, B, C)
Study: 15978972
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 160 mg/day
Study: 15072869
Drug: Propionyl‐L‐carnitine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl‐L‐carnitine 2 g/day plus acetyl‐L‐carnitine 2 g/day
Study: 2107926
Drug: Tacrine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (mean of 114 mg daily) and lecithin (1200 mg daily)
Study: 2107926
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and lecithin (1200 mg daily)
Study: 30933384
Drug: 980‐nm diode
Approvals — FDA: no, EMA: no, PMDA: no
Description: 980‐nm diode laser (DL) irradiation in combination with mechanical therapy (setting 980 nm, 2.5 W, 10 kHz, pw, 30 s)